Vanguard Asset Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.29M Buy
228,653
+22,634
+11% +$209K ﹤0.01% 1488
2026
Q2
$1.72M Sell
206,019
-6,450
-3% -$58.8K ﹤0.01% 1622
2026
Q1
$1.91M Buy
+212,469
New +$3.35M ﹤0.01% 1492

Other funds holding ADMA

Vanguard Asset Management's ADMA Position: Q3 2026 in Review

Vanguard Asset Management increased its ADMA Biologics (ADMA) stake by 11% in Q3 2026, buying an estimated $209K and bringing the position to 228,653 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Vanguard Asset Management first reported a position in ADMA in Q1 2026 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Vanguard Asset Management held 228,653 shares of ADMA Biologics worth $2.29M as of Q3 2026.
  • Vanguard Asset Management bought 22,634 ADMA Biologics shares in Q3 2026, an estimated $209K.
  • ADMA Biologics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1488 holding.
  • Vanguard Asset Management first reported a position in ADMA Biologics in Q1 2026 and has held it in 3 quarters since.
  • 329 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.